Table 2:

Morphometric assessment

All CELs (n = 54)Gliomas (n = 38)Metastases (n = 16)
TV (median/IQR) (mL)
    MPRAGE1.36/0.18–10.933.02/0.44–28.930.33/0.006–2.81
    SPACE1.78/0.20–11.003.5/0.49–29.730.39/0.006–3.2
    VIBE1.62/0.16–10.353.39/0.43–27.480.40/0.007–2.84
TV, SPACE vs MPRAGE
    Pa.001b.007b.003b
    P (adjusted for sequence acquisition order)c.034b.033b.075
TV, VIBE vs MPRAGE
    Pa.259.201.343
    P (adjusted for sequence acquisition order)c.521.538.706
MED (median/% of TV)
    |CELMPRAGE|–|CELSPACE|0.10 mL/7.4%0.18 mL/6%0.02 mL/6.1%
    |CELSPACE|–|CELMPRAGE|0.27 mL/19.9%0.43 mL/14.2%0.05 mL/15.2%
    |CELMPRAGE|–|CELVIBE|0.15 mL/11%0.21 mL/7%0.01 mL/3%
    |CELVIBE|–|CELMPRAGE|0.15 mL/11%0.23 mL/7.6%0.05 mL/15.2%

  • Note:—MED indicates margin extent discrepancy; IQR, interquartile range.

  • ↵a Wilcoxon signed rank test.

  • ↵b Statistically significant differences.

  • ↵c General Linear Model.